Skip to main content
Top
Published in: Breast Cancer Research 1/2000

01-12-2000 | Paper Report

An anti-oncogenic role for decorin

Author: Karen Schmeichel

Published in: Breast Cancer Research | Issue 1/2000

Login to get access

Excerpt

Decorin, a luecine-rich proteoglycan, is normally produced by cells in the breast tissue stroma where it is thought to play a role in matrix assembly, growth factor binding and receptor tyrosine kinase activity. Its expression pattern is consistent with a role in antagonizing cell growth and thus curbing tumor-associated behaviors. Previous studies demonstrated that one mechanism by which decorin exerts its growth-suppressive effects is via interaction with the ErbB family receptor tyrosine kinase, EGFR. However, because decorin expression also appears to influence cells that lack EGFR (eg the breast carcinoma cell line MDA-MB-453) it seemed likely that decorin might exhibit similar effects by acting cooperatively with other related ErbB family members. …
Literature
1.
go back to reference Santra M, Eichstetter I, Iozzo RV: An anti-oncogeneic role for decorin: downregulation of ErbB2leads to growth suppression and cytodifferentiation of mammary carcinoma cells. J Biol Chem. 2000, 275: 35153-35161.CrossRefPubMed Santra M, Eichstetter I, Iozzo RV: An anti-oncogeneic role for decorin: downregulation of ErbB2leads to growth suppression and cytodifferentiation of mammary carcinoma cells. J Biol Chem. 2000, 275: 35153-35161.CrossRefPubMed
Metadata
Title
An anti-oncogenic role for decorin
Author
Karen Schmeichel
Publication date
01-12-2000
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 1/2000
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr-2000-66720

Other articles of this Issue 1/2000

Breast Cancer Research 1/2000 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine